Immunomedics, Inc. - Product Pipeline Review - 2014

Published: Jan, 2014 | Pages: 67 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Summary

Global Market Direct's pharmaceuticals report, "Immunomedics, Inc. - Product Pipeline Review - 2014" provides data on the Immunomedics, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Immunomedics, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from Immunomedics, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Immunomedics, Inc. - Brief Immunomedics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Immunomedics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Immunomedics, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Immunomedics, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Immunomedics, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Immunomedics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Immunomedics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Immunomedics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Immunomedics, Inc. and identify potential opportunities in those areas.

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Immunomedics, Inc. Snapshot 6
Immunomedics, Inc. Overview 6
Key Information 6
Key Facts 6
Immunomedics, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Immunomedics, Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Immunomedics, Inc. - Pipeline Products Glance 15
Immunomedics, Inc. - Late Stage Pipeline Products 15
Phase III Products/Combination Treatment Modalities 15
Immunomedics, Inc. - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Immunomedics, Inc. - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
Immunomedics, Inc. - Drug Profiles 20
epratuzumab 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
yttrium Y 90 clivatuzumab tetraxetan 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
IMMU-130 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
IMMU-132 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
veltuzumab 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
IMMU-110 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
milatuzumab 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
TF-2 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
IMMU-114 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
1R-(15)-(15) 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
1R-(E1)-(E1) 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Interferon Lambda-1 Linked Fab Dimer 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
TF-12 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
hA19 Antibody 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Immunomedics, Inc. - Pipeline Analysis 44
Immunomedics, Inc. - Pipeline Products by Therapeutic Class 44
Immunomedics, Inc. - Pipeline Products by Target 46
Immunomedics, Inc. - Pipeline Products by Route of Administration 48
Immunomedics, Inc. - Pipeline Products by Molecule Type 49
Immunomedics, Inc. - Pipeline Products by Mechanism of Action 50
Immunomedics, Inc. - Recent Pipeline Updates 52
Immunomedics, Inc. - Dormant Projects 62
Immunomedics, Inc. - Discontinued Pipeline Products 63
Discontinued Pipeline Product Profiles 63
veltuzumab 63
Immunomedics, Inc. - Company Statement 64
Immunomedics, Inc. - Locations And Subsidiaries 65
Head Office 65
Other Locations & Subsidiaries 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 67
Disclaimer 67

List of Tables
Immunomedics, Inc., Key Information 6
Immunomedics, Inc., Key Facts 6
Immunomedics, Inc. - Pipeline by Indication, 2014 9
Immunomedics, Inc. - Pipeline by Stage of Development, 2014 11
Immunomedics, Inc. - Monotherapy Products in Pipeline, 2014 12
Immunomedics, Inc. - Partnered Products in Pipeline, 2014 13
Immunomedics, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 14
Immunomedics, Inc. - Phase III, 2014 15
Immunomedics, Inc. - Phase II, 2014 16
Immunomedics, Inc. - Phase I, 2014 17
Immunomedics, Inc. - Preclinical, 2014 18
Immunomedics, Inc. - Discovery, 2014 19
Immunomedics, Inc. - Pipeline by Therapeutic Class, 2014 45
Immunomedics, Inc. - Pipeline by Target, 2014 47
Immunomedics, Inc. - Pipeline by Route of Administration, 2014 48
Immunomedics, Inc. - Pipeline by Molecule Type, 2014 49
Immunomedics, Inc. - Pipeline Products by Mechanism of Action, 2014 51
Immunomedics, Inc. - Recent Pipeline Updates, 2014 52
Immunomedics, Inc. - Dormant Developmental Projects,2014 62
Immunomedics, Inc. - Discontinued Pipeline Products, 2014 63
Immunomedics, Inc., Other Locations 65
Immunomedics, Inc., Subsidiaries 65